Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Date:7/24/2008

PITTSBURGH, July 24 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, August 6, 2008, at 10:30 a.m. ET to provide a review of the second quarter ended June 30, 2008. The company will release its financial results before the market opens August 6.

The dial-in number to access the August 6 call is 877-741-4241 or 719-325-4787 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 8142044.

To access a live webcast of the August 6 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately seven days.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
2. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
3. Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
4. Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
5. Mylan Wins Generic Prilosec(R) Patent Litigation
6. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
7. Mylan Announces Final FDA Approval for Zaleplon Capsules
8. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
9. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... the New England Journal of Medicine and NEJM Journal Watch, announces the release ... Review was created by a panel of pediatricians from leading medical centers. The ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... management program at Women’s Excellence will help patients lose weight and keep it ... The specialists at Women's Excellence will measure BMI, body fat composition, and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Janet Schloz is still in shock after receiving ... days I’ve had in a long time,” she said. , She thinks the coming week ... that I never thought I would have to help my students.” , The award will ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... settlement agreement to resolve the pending litigation between itself and 1800 Vending DBA ... of Utah). , “I am thrilled to announce that we have now reached ...
(Date:3/26/2017)... ... March 26, 2017 , ... ... the RealSelf 100 Award, a prestigious award honoring the top influencers on RealSelf—the ... find and connect with doctors and clinics. , In 2016, more than 82 ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... 2017 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... that AGI-134, an immunotherapy for the treatment of multiple cancers, ... be featured at the upcoming American Association for Cancer ... to be held on April 1-5, 2017. ... An abstract ...
(Date:3/27/2017)... -- The global clinical chemistry analyzers ... 2025, according to a new study by Grand View ... anticipated to be responsible for the high urgency to ... for growth during the forecast period. In addition, growing ... susceptible to chronic diseases, is presumed to impel the ...
Breaking Medicine Technology: